Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects-Reference-Cited by-同舟云学术

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects

Published:2019-07-19 Issue:4 Volume:84 Page:749-757
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Aslanis Vassilios,Umehara Kenichi,Huth Felix,Ouatas Taoufik,Bharathy Savita,Butler Andrew Avigdor,Zhou Wen,Gadbaw Brian

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03907-1.pdf

Reference24 articles.

1. Zhou T, Georgeon S, Moser R, Moore DJ, Caflisch A, Hantschel O (2014) Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348). Leukemia 28:404–407. https://doi.org/10.1038/leu.2013.205

2. US Food and Drug Administration (2011) Jakafi prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf . Accessed 22 Feb 2018

3. Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24:133–145. https://doi.org/10.1016/j.cytogfr.2013.01.004

4. Seavey MM, Dobrzanski P (2012) The many faces of Janus kinase. Biochem Pharmacol 83:1136–1145. https://doi.org/10.1016/j.bcp.2011.12.024

5. Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613. https://doi.org/10.1038/onc.2012.347

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease;Transplantation and Cellular Therapy;2024-05

2. Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma;Journal of Chromatography B;2023-11

3. Recommendations on the use of azole antifungals in hematology-oncology patients;Revista Española de Quimioterapia;2023-04-05

4. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review;Clinical Pharmacokinetics;2023-03-31

5. Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions;Cancer Chemotherapy and Pharmacology;2022-12-13